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The human immunodeficiency virus type 1 (HIV-1) Tat protein is a transcriptional activator that is essential for efficient viral
gene expression and replication. Tat increases the level of full-length transcripts from the HIV-1 promoter by dramatically
enhancing the elongation efficiency of the RNA polymerase II complexes assembled on this promoter. Tat could potentially
activate the transcription machinery during initiation, elongation, or both. We used an immobilized HIV-1 promoter template
with a reversible lac repressor (LacR) elongation block inserted downstream to dissect the stages in transcription affected
by Tat. Transcription complexes assembled in the absence of Tat and blocked by LacR cannot be activated by incubation with
Tat alone. These complexes can, however, be activated if Tat is added in combination with cellular factors. In this system,
Tat also promoted the assembly of preinitiation complexes capable of elongating efficiently, suggesting that Tat can
associate with transcription complex at an early stage. These data indicate that Tat can activate elongation of RNA
polymerase by modifying an already elongating transcription complex. The data also suggest the possibility that Tat can
interact with initiation complexes. © 1999 Academic Press
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Human immunodeficiency virus type 1 (HIV-1) gene
xpression is regulated by the viral Tat protein, which
cts in trans to specifically increase the synthesis of full
ength HIV-1 transcripts in vivo and in vitro (Arya et al.,
985; Marciniak et al., 1990; Sodroski et al., 1985; Sun˜e´
nd Garcia-Blanco, 1995). Tat functions by binding to a
9-nucleotide (nt) RNA element designated TAR, which
tands for transactivation response element (Berkhout et
l., 1989; Cullen, 1990; Gaynor, 1995). TAR forms a stem-
ulge-loop structure located at the 59 end of all HIV-1
ranscripts (Rosen et al., 1985; Selby et al., 1989); se-
uences within the loop and the bulge, as well as ele-
ents of structure within the stem, are required in cis for
at action (Berkhout and Jeang, 1989; Feng and Holland,
988; Marciniak et al., 1990). Transactivation by Tat re-
uires specific proteins distinct from general transcrip-
ion factors (Carroll et al., 1992; Madore and Cullen, 1993;
un˜e´ and Garcia-Blanco, 1995; Zhou and Sharp, 1995),
nd several human Tat cofactors have recently been
urified (Sun˜e´ et al., 1997; Wei et al., 1998; Zhu et al.,
997; Zhou and Sharp, 1996).
Tat increases the level of long transcripts while not
ignificantly increasing the level of promoter proximal
hort transcripts; thus, the major effect of Tat is to in-
1 To whom reprint requests should be addressed at, Box 3686, Duke
niversity Medical Center, Durham, NC 27710. Fax: (919) 613-8646.e-mail: garci001@mc.duke.edu.
337rease the elongation efficiency of the RNA polymerase
I complex (Feinberg et al., 1991; Kato et al., 1992; Mar-
iniak and Sharp, 1991; Zhu et al., 1997). Nevertheless, a
eak effect on initiation has also been noted (Zhu et al.,
997). Although the final outcome of Tat action is known,
he mechanism by which Tat enhances elongation is
oorly understood.
There is some evidence that the elongation effect of
at may be determined in part during transcription initi-
tion. Deletion of upstream enhancers and sequence
ariations of the TATA element specifically inhibit Tat-
ctivated transcription (Berkhout and Jeang, 1992; Lu et
l., 1993; Olsen and Rosen, 1992), suggesting that these
lements, usually associated with the assembly of the
reinitiation complex, play a role in Tat-activated elonga-
ion. Previously, it has been shown that transcription
ctivators such as VP16 and E2F1, which mediate their
ction via upstream-activating sequences, can affect
oth initiation and elongation efficiency (Blair et al., 1996;
lau et al., 1996; Yankulov et al., 1994). In fact, Tat inter-
cts with transcription factors that mediate the assembly
f preinitiation complexes on the HIV-1 promoter and
ith factors usually associated with initiation of tran-
cription (Garcia-Martinez et al., 1997; Kashanchi et al.,
994; Veschambre et al., 1997). Tat also specifically in-
eracts with RNA polymerase II holoenzyme in the ab-
ence of transcription (Cujec et al., 1997a; Sun˜e´ et al.,
997). Interaction between Tat and TFIIH, a factor that
ay be critical for the transition between initiation andlongation (Dvir et al., 1996, 1997; Goodrich and Tjian,
0042-6822/99 $30.00
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338 LIU, SU, AND GARCIA-BLANCO994), has been reported (Cujec et al., 1997b; Garcia-
artinez et al., 1997; Parada et al., 1996). CA150, a factor
inked to Tat action in vivo and in vitro, associates with
NA polymerase II complexes (Goldstrohm et al., manu-
cript submitted; Sun˜e´ et al., 1997). Taken together, these
tudies support an early interaction of Tat with the tran-
cription machinery and open the possibility that Tat
romotes the assembly of elongation competent com-
lexes on the HIV-1 promoter (Cullen, 1993).
More observations link Tat action to the stage of tran-
cription elongation. Using a pulse-chase analysis in the
n vitro transcription assay, Kato et al. (1992) suggested
hat Tat could activate an elongating RNA polymerase in
manner analogous to that of TFIIF. It has also been
ostulated that Tat acts on the elongating transcription
omplex as an antitermination factor (Kao et al., 1987)
imilar to the phage lambda N protein (Greenblatt et al.,
993); however, a specific terminator sequence has not
een identified in the HIV-1 promoter. Factors that mod-
late elongation of transcription complexes have been
valuated to search for cellular targets of Tat action. The
iscoveries that Tat can bind a CTD kinase complex
Tat-associated kinase (TAK)] (Herrmann and Rice et al.,
993, 1995; Yang et al., 1996) and that TAK is the positive-
cting transcription elongation factor complex P-TEFb
Mancebo et al., 1997; Marshall and Price, 1995; Yang et
l., 1997; Zhu et al., 1997) have linked CTD phosphoryla-
ion to the regulation of HIV-1 transcription elongation.
he cyclin subunit of TAK interacts specifically with Tat
nd enhances its affinity for TAR binding (Wei et al.,
998), and both the catalytic subunit of P-TEFb (Mancebo
t al., 1997; Yang et al., 1997; Zhu et al., 1997) and its
ssociated nuclear cyclin (Wei et al., 1998) have been
hown to be important for Tat-mediated transcription
ctivation. Because P-TEFb is involved in elongation con-
rol (Marshall and Price, 1995; Marshall et al., 1996),
hese findings have led to the suggestion that Tat inter-
cts with the elongating polymerase modifying its effi-
iency. Consistent with a function in elongation, Tat has
een shown to be an integral component of transcription
longation complexes (Keen et al., 1996).
To functionally distinguish the different stages of tran-
cription and to determine the effect of Tat at these
tages, we used an in vitro transcription system with an
mmobilized HIV-1 template and reversible elongation
locks (two tandem LacO sites). A similar system has
een used by Keen et al. (1996, 1997) to address the
resence of Tat and TAR in the elongation complex;
owever, the functional involvement of Tat at different
tages has not been studied by these authors. Here, we
how that purified paused elongation complexes cannot
e activated during elongation by Tat alone. Tat in com-
ination with cellular factor or factors, however, can
ctivate these transcription complexes arrested in the
longation stage. Thus we conclude that Tat in combi-
ation with cellular factors can regulate a paused poly- oerase and by extension speculate that Tat could acti-
ate an actively elongating polymerase. It is very likely
hat the required cellular factors include P-TEFb subunits
Wei et al., 1998; Zhu et al., 1997) and possibly other
oactivators such as Tat-SF1 and CA150 (Sun˜e´ et al.,
997; Zhou et al., 1996). We were surprised by a second
esult, which suggested a possible earlier role for Tat.
ranscription complexes assembled in the presence of
at produced 3-fold higher levels of full-length HIV-1
ranscripts than those formed in the absence of Tat. The
longation properties of the complexes seem intrinsic
ecause purification of these during elongation does not
iminish Tat activation. Our data support a model by
hich Tat can recruit cellular factors, minimally P-TEFb,
t different stages of transcription.
RESULTS
at increased the elongation efficiency of
ranscription complexes on immobilized templates
To identify the stage of transcription at which Tat acts, we
stablished an in vitro transcription system with an immo-
ilized HIV-1 template and a reversible elongation block
Fig. 1). DNA templates containing the HIV-1 promoter were
mmobilized on a solid phase via a biotin–streptavidin in-
eraction 466 nt upstream of the transcription initiation site.
his allowed the sequential addition of factors and the
ubsequent removal of unbound factors through washes.
reinitiation complexes were formed by incubating the im-
obilized HIV-1 templates with HeLa nuclear extract (see
aterials and Methods and Fig. 1). After three washes,
ranscription commenced on the addition of NTPs and
a-32P]UTP, revealing that the assembled preinitiation com-
lexes contained all the factors required for producing
ull-length (1190 nt) HIV-1 run-off transcripts (Fig. 2A, lane 1).
hen the preinitiation complexes were assembled in the
resence of Tat, 4.5-fold more full-length transcripts were
ynthesized (Fig. 2A, lane 2).
To further analyze Tat action, we inserted two consec-
tive LacO sequences into the HIV-1 template at position
79 and 1111 downstream of the transcription initiation
ite (Fig. 1). Template-bound LacR protein has been
hown to arrest an elongating RNA polymerase II in vitro
nd in vivo (Deuschele et al., 1990; Keen et al., 1996;
eines and Mote, 1993). To confirm the block of RNA
olymerase II elongation by LacR in our system, a pulse-
hase experiment was performed. After assembling the
reinitiation complexes, transcription was initiated with
he addition of NTPs and [a-32P]UTP for 1 min. The
omplexes were washed three times, and radiolabeled
ascent transcripts were chased with unlabeled NTPs
nder transcription conditions for 8 min. Transcripts with
engths corresponding to transcriptional arrest at the two
acO sites were detected and represented ;80% of all
ranscripts observed (Fig. 2B, lane 1). The remaining 20%
f transcripts were detected as a continuum of longer
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339TAT ACTIVATION OF RNA POLYMERASE II COMPLEXESpecies, which are not clearly visible in the exposure
hown here. This result confirmed that the elongation of
NA polymerase II transcription complexes could be
locked by LacR, although the block was not complete
Fig. 2B, lane 1) (Deuschele et al., 1990; Keen et al., 1996).
In the presence of isopropyl-b-D-thiogalactoside
IPTG), which increases the rate of dissociation of LacR
rom LacO sites (Riggs et al., 1970), the majority of the
aused short transcripts were released from the block
nd elongated; however, the short transcripts were not
hased efficiently to full-length transcripts of 1190 nt (Fig.
B, lane 3). Because washes were carried out after the
ulse with [a-32P]UTP and because only unlabeled NTPs
ere added during the chase, the longer transcripts
bserved were exclusively derived from the paused tran-
cription complexes and not from transcription reinitia-
ion. To further confirm this, an adenovirus major late
romoter template was added to the reaction after the
ash. Transcripts derived from the added adenovirus
ajor late template were not observed during a chase
ith radiolabeled NTPs (data not shown). We therefore
oncluded that transcription complexes paused at the
acO sites were capable of resuming elongation on the
FIG. 1. The immobilized in vitro transcription system. The biotinyla
equences was immobilized on streptavidin-coated plates, and in vitr
LacR). Preinitiation complexes were formed in the presence of NE, fol
arried out with the addition of ribonucleotides and [a-32P]UTP (*NTPs),
o reach the LacR block. The reactions containing LacR were washed,
nlabeled ribonucleotides (cold NTPs) were added at the same time t
eaction as indicated.emoval of LacR. pWhen Tat was added together with nuclear extract
uring preinitiation complex formation in the absence of
PTG, the number of transcripts paused at the LacR was
ot affected (Fig. 2B, lane 2). There was a minute in-
rease in the number of full-length transcripts, which
robably resulted from the increased elongation effi-
iency of those transcription complexes that were not
rrested at the LacR block. In the presence of IPTG, the
ddition of Tat increased the formation of full-length
ranscripts by 3-fold (Fig. 2B, lane 4). The fold of Tat
ctivation is consistent with a report using a similar
ystem (Keen et al., 1997). Therefore, Tat can increase
he elongation efficiency of transcription complexes on
his immobilized template.
unctional effect of Tat during transcription
longation
From the experiments described above, we concluded
hat Tat enhanced the formation of full-length transcripts
n this immobilized template system. To assay whether
at could activate transcription complexes already in the
longation phase, we performed experiments with com-
V-1 template with the inserted two consecutive lac operator (LacO)
cription was carried out in the absence or presence of lac repressor
by washes of the reaction matrix when indicated. RNA synthesis was
o the full length or for a short time to allow the transcription complexes
G was added to some experiments to dissociate LacR from the DNA.
the transcription to continue. Tat was added at different steps of theted HI
o trans
lowed
either t
and IPT
o allowlexes blocked at the LacO sites. These complexes were
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340 LIU, SU, AND GARCIA-BLANCOashed to remove free nuclear extract factors remaining
n the reactions. When added to the arrested transcrip-
ion complexes together with unlabeled NTPs and IPTG,
at did not activate elongation efficiency (data not
FIG. 2. Pausing and release of transcription complexes at the LacR
nd the effect of Tat when added early in transcription. (A) Transcription
eactions were carried out as diagrammed at the top and as described.
reinitiation complexes were formed either in the absence (lane 1) or
resence (lane 2) of 400 ng of Tat. The template was washed and RNA
ynthesis was performed for 9 min. (B) After incubation of LacR with the
emplate, preinitiation complexes were formed either in the absence
lanes 1 and 3) or presence (lanes 2 and 4) of Tat. RNA synthesis was
nitiated for 1 min. After washing, the paused transcription complexes
ere chased with cold NTPs, either in the absence (lanes 1 and 2) or
resence (lanes 3 and 4) of IPTG. Radiolabeled transcripts were sep-
rated on a denaturing gel. The migration of full-length (1190 nt) and
acR “paused” transcripts are indicated by an arrow and by asterisks,
espectively. Molecular size markers (lane M, in base pairs) were the
BR322 DNA-MspI digest labeled with [a-32P]dCTP. The data shown in
were quantified on a PhosphorImager, and the total number of counts
n each lane varied by ,10%.hown). Even if Tat was incubated with the blocked tomplexes for 20 min before the addition of unlabeled
TPs and IPTG, no activation was observed (Fig. 3A,
ane 3). The dose of Tat was 5–500 ng/25-ml reaction;
ctivation by Tat was not observed at any concentration
data not shown). Thus transcription complexes formed
n the absence of Tat and arrested at the LacO sites were
ot intrinsically capable of responding to Tat addition.
Because the washes should remove many factors not
resent in the arrested elongation complexes yet neces-
ary for the action of Tat, varying amounts of nuclear extract
2–10 ml) were added to the paused complex together with
at, unlabeled NTPs, and IPTG. When nuclear extract was
ncubated with the paused complex for 20 min before the
ddition of NTPs and IPTG, there was a minimal enhance-
ent in the formation of full-length transcripts (Fig. 3A, lane
). In contrast, Tat and nuclear extract incubated together
ith the paused complex for 20 min enhanced the forma-
ion of full-length transcripts (Fig. 3A, lane 5). Results from
everal experiments were quantified and are presented in
ig. 3B. This activation effect was Tat specific because the
41A Tat mutant did not increase the level of full-length
ranscripts (data not shown).
An intact TAR element is absolutely required for Tat
ctivation in vivo and in vitro (Berkhout et al., 1989; Berkhout
nd Jeang, 1989; Cullen, 1990; Feng and Holland, 1988;
arciniak et al., 1990; Rosen et al., 1985; Selby et al., 1989).
o verify that the observed Tat function was TAR specific,
e used a template carrying a mutation in the loop region
f TAR RNA (TAR 31/34), which eliminates Tat-dependent
ctivation in vitro and in vivo (Feng and Holland, 1988;
arciniak et al., 1990). Incubation of Tat and nuclear extract
ith the blocked complexes assembled on the TAR 31/34
utant template did not result in activation (data not
hown). Therefore, this Tat activation effect was also de-
endent on a functional TAR, which probably was still at-
ached to the paused complex at position 179. When the
acR block was at nt 1280, the activation effect of Tat and
uclear extract diminished to 1.5-fold (data not shown),
hich was consistent with the result that TAR is not stably
ethered to the transcription complex when it moves further
nto elongation (Keen et al., 1997).
The results above indicated that once the transcription
omplex that assembled in the absence of Tat had
assed the initiation stage, Tat by itself was not able to
ctivate it. In combination with cellular coactivator or
oactivators, however, Tat could activate a transcription
omplex arrested in elongation at the LacO sites.
urprisingly, Tat can also latently activate RNA
olymerase II complexes before initiation of
ranscription
To determine whether Tat could exert an effect during
he initiation phase, we performed experiments with tem-
lates that had been washed three times after preinitia-ion complex formation to prevent any free Tat from
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341TAT ACTIVATION OF RNA POLYMERASE II COMPLEXEScting at subsequent steps (Fig. 4A). The level of full-
ength transcripts was increased when Tat was present
uring preinitiation complex formation (Fig. 4A, lane 3).
he finding that the Tat effect was not influenced by the
ashing step indicated that Tat was able to stably inter-
ct with components of the preinitiation complex or that
at modified the complexes in a manner that was resis-
ant to the washes.
Because nuclear extract may contain free ribonucle-
tides, there was a possibility that the complexes may
ave progressed beyond the preinitiation stage even in
he absence of exogenously added NTPs. To assess this
ossibility, the HIV-1 template was incubated with nu-
FIG. 3. The effect of Tat on paused elongation complexes. (A) After
as incubated for 20 min in the absence (lanes 1 and 2) or presence o
hen was chased with cold NTPs in the absence (lane 1) or presence
xperiments is shown in graphic form. The error bars represent standlear extract in the presence of 10 mCi of [a-32P]GTP for t0 min at 30°C. No transcripts were observed (data not
hown). We also treated the nuclear extract with hexoki-
ase and glucose to deplete the endogenous ATP (Fig.
C, left, lane 3). In fact, ATP could also be depleted by
ndogenous kinases in the nuclear extract (Fig. 4C, left,
ane 2). The hexokinase-treated nuclear extract sup-
orted Tat activation to the same level as the untreated
xtract in our immobilized in vitro transcription system
Fig. 4C, right). These results suggested that all factors
equired for Tat-dependent activation of elongation com-
etence could be assembled during the preinitiation in
he presence of Tat.
The addition of Tat during preinitiation complex forma-
tion complex formation, 1-min pulse labeling, and wash, the reaction
ane 3), nuclear extract (lane 4), or Tat and nuclear extract (lane 5) and
2–5) of IPTG. (B) Quantification of data from A and two other identical
or. The observed significance level (P) is , .05.preinitia
f Tat (l
(lanesion made the transcription complex more elongation
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342 LIU, SU, AND GARCIA-BLANCOompetent if the template encoded a wild-type TAR ele-
ent (Figs. 4A, lanes 1–3, and 4B). With the TAR 31/34
emplate, the addition of Tat did not change the amount
f full-length transcripts (Figs. 4A, lanes 4–6, and 4B).
nother template carrying the inactive bulgeless TAR
utation was also tested, and as expected, no Tat acti-
ation effect was observed (data not shown). To confirm
hat the observed transactivation resulted from Tat activ-
ty, K41A, an inactive mutant of Tat (Marciniak et al., 1990;
ice and Carlotti, 1990), was added during preinitiation
FIG. 4. Tat functions as early as preinitiation complex formation, an
rotein. (A) Equal amounts of wild-type (lanes 1–3) or TAR loop 31/34 m
omplexes were formed in the absence (lanes 1, 2, 4, and 5) or presenc
ynthesis was initiated briefly, the reactions were washed again, and
bsence (lanes 1 and 4) or presence (lanes 2, 3, 5, and 6) of IPTG. (B)
emplates, as well as Tat mutant (K41ATat) reactions, is shown in g
upplemented NE was treated either with glucose alone (lane 2)
hromatographic analysis. Lane 1 shows the corresponding amount o
tandards is indicated. Right: NE or hexokinase-treated NE (H-NE) was
s the same as in A.omplex formation, and it did not increase the amount of aull-length transcripts (Fig. 4B). Therefore, the transacti-
ation effect obtained in these experiments was depen-
ent on the presence of functional Tat and TAR.
DISCUSSION
It is clear from the work of others and from the present
ork that Tat primarily enhances transcriptional elonga-
ion efficiency (Feinberg et al., 1991; Kato et al., 1992;
arciniak and Sharp, 1991; Zhu et al., 1997). How Tat
ffect is dependent on a functional TAR element and a functional Tat
(lanes 4–6) HIV-1 template were added to the reactions. Preinitiation
3 and 6) of Tat, followed by washes to remove unbound factors. RNA
ription elongation resumed in the presence of cold NTPs and in the
ication of the data from wild-type (wtTAR) and mutant TAR (TAR31/34)
form. The error bars represent standard error. (C) Left: [a-32P]ATP-
glucose and hexokinase (lane 3) and was subject to thin-layer
]ATP added to NE before treatment. The migration of ribonucleotide
during preinitiation complex formation. The experimental procedured the e
p utant
c e (lanes
s transc
a Quantif
t raphic
s or with
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iccomplishes this goal has been a matter of much de-
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343TAT ACTIVATION OF RNA POLYMERASE II COMPLEXESate: Is Tat an “elongation factor,” acting on a transcribing
r paused polymerase, or is Tat an “initiation factor,”
cting on a polymerase complex that is being assembled
n the vicinity of the transcription start site? In this work,
e set up an immobilized in vitro transcription system to
issect different stages in transcription and to study the
ffect of Tat at these stages. We have clearly shown that
at can activate the RNA polymerase complex during
arly elongation. Our data, however, also argue for a
ossible earlier effect of Tat.
The early elongation complex that has assembled
ithout Tat (E2 complex) is unable to elongate effi-
iently. When paused at the LacR block at position 179
rom the start site of transcription, the paused elongation
omplex cannot be activated by Tat alone. It has been
hown that the interaction of Tat with cyclin T, the cyclin
FIG. 4ubunit of P-TEFb, strongly enhances the affinity and hpecificity of Tat–TAR interaction (Wei et al., 1998). There-
ore, the lack of activation is probably due to the missing
f necessary cofactors, very likely P-TEFb. Other Tat
oactivators, like CA150 and Tat-SF1, may also be impor-
ant. P-TEFb binds to wild-type but not mutant TAR only in
he presence of Tat (Fujinaga et al., 1998). This agrees
ith our finding that the paused elongation complex
annot be activated by nuclear extract alone. When Tat
nd nuclear extract are added together, they are able to
orm a complex, which leads to cooperative Tat–TAR–
ellular factor binding. The E2 complex is then switched
o the elongation competent state when chased with
ibonucleotides, possibly through efficient phosphoryla-
ion of the RNA polymerase II CTD by CDK9, a subunit of
-TEFb (Zhu et al., 1997).
An unexpected finding derived from our experiments
nuedas been the effect of Tat during preinitiation complex
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344 LIU, SU, AND GARCIA-BLANCOormation. Our results suggest that Tat can set up the
ctivation of HIV-1 transcription during the formation of a
reinitiation complex, thus suggesting that Tat can direct
he assembly of a latent elongation competent transcrip-
ion complex during initiation. The association between
at and the RNA polymerase II holoenzyme complex
Cujec et al., 1997a; Sun˜e´ et al., 1997) and the presence
f Tat in preinitiation complexes (Garcia-Martinez et al.,
997) support this hypothesis. Our data also indicate that
ll the factors required for Tat trans-activation can be
ssembled at the preinitiation stage. Although it is clear
hat P-TEFb is involved in elongation control (Marshall et
l., 1996; Marshall and Price, 1995), it may already be
ssociated with RNA polymerase during initiation. In fact,
e have found that P-TEFb associates with an RNA
olymerase II complex in the absence of transcription
nd Tat (Goldstrohm et al., submitted for publication). Our
ata reveal that an elongation complex that was origi-
ally assembled in the presence of Tat (E1 complex) can
longate efficiently, whereas the complex originally as-
embled without Tat (E2 complex) cannot. This is not
olely accounted for by the presence of Tat because the
ddition of Tat alone in elongation stage cannot activate
he E2 complex. Our assumption is that the presence of
at in the preinitiation complex either recruits necessary
ofactors or slows down the dissociation rate of the
ofactors from RNA polymerase complex, thus making
1 complex elongation competent. It should be noted
hat we could not, however, formally exclude the possi-
ility that Tat, together with its associated cellular cofac-
ors, binds to the HIV-1 template nonspecifically and
emains passive until TAR is transcribed.
What is the function of TAR? Our data clearly indicate
hat unless the transcript encodes a functional TAR, Tat
ctivation is not executed. We have previously shown
hat TAR decoys inhibited Tat-activated transcription after
reinitiation complex formation but not before this, prob-
bly by preventing endogenous TAR from interacting with
at-containing elongation complexes (Bohjanen et al.,
997). Studies using a similar experimental system have
hown that Tat is associated with the activated transcrip-
ion elongation complex (Keen et al., 1996), whereas TAR
s not stably tethered to this complex during elongation
Keen et al., 1997). Our data, together with these results,
ead us to propose the following: when Tat and nuclear
xtract are added to the paused E2 elongation complex,
ascent TAR helps recruit the Tat–cofactors complex
hrough cooperative binding, directs them to the RNA
olymerase, and makes the complex elongation compe-
ent. For the E1 complex, nascent TAR functions via
ooperative binding to stabilize the association of Tat
ofactors with the early elongation complex and in so
oing activates the elongation competent state of tran-
cription complex that has been set up by Tat . eMATERIALS AND METHODS
mmobilization of the templates
Plasmid pBC12/HIV/SEAP (Berger et al., 1988) was
odified by the insertion of two consecutive lac operator
LacO) sequences (TGTGGAATTGTGAGCGGATAACAA-
TTCACGTCGACG) at a HindIII site (nt 179) downstream
f the TAR element. This plasmid was used as a template
or PCR. The PCR product, which extended from 2466 to
1190 relative to the HIV-1 transcription start site, was
igested with EcoRI at the 2466 site and was biotinyl-
ted with biotin-14-dATP (GIBCO BRL) using the Klenow
ragment of DNA polymerase I. This served as the wild-
ype template for in vitro transcription. The TAR 31/34
emplate contained a TGGG-to-CAAA substitution (Mar-
iniak et al., 1990) in the sequences corresponding to the
AR loop region and was otherwise identical to the wild-
ype. The bulge was removed in the bulgeless TAR tem-
late by insertion of a complementary sequence in the
tem region. The biotinylated template (250 ng) was
dded to each well of streptavidin-coated microplates
Labsystems) in 25 ml of binding buffer (0.1% BSA, 0.1%
ween 20, in PBS). The wells were rocked at room
emperature for 1 h and washed three times with 75 ml of
uffer D (20 mM HEPES, pH 7.9, 0.1 M KCl, 0.2 mM EDTA,
H 8.0, 0.5 mM DTT, and 20% v/v glycerol).
n vitro transcription
In Fig. 2A, preinitiation complexes were formed by
dding to each well 25 ml of a solution containing 40%
v/v) of HeLa cell nuclear extract (NE) (Sun˜e´ and Gar-
ia-Blanco, 1995) and 4 mM sodium citrate in buffer D.
fter incubation at 30°C for 20 min, the wells were
ashed three times with 75 ml of wash buffer (100
g/ml phenylmethylsulfonyl fluoride and 0.1% v/v Non-
det-P40 in buffer D). Transcription was carried out for
min in 25 ml of a solution containing 15 mM NaCl, 7
M MgCl2, 4 mM sodium citrate, 1 mM DTT, 10 mM
reatine phosphate, 250 ng of poly(I)/poly(C), 300 ng of
oly(dI)/poly(dC), 625 mM concentration each of ATP,
TP, and CTP, 40 mM UTP, and 10 mCi of [a-32P]UTP
ICN) in buffer D. In all other experiments, the immo-
ilized template was incubated with 1 mg of LacR (a
enerous gift from Dr. Kathleen Matthews, Rice Uni-
ersity) in 25 ml of buffer D at 30°C for 20 min. The
olution was removed, and the template was incu-
ated with a 25 ml of a solution containing 40% (v/v) of
E in buffer D supplemented with 4 mM sodium citrate
t 30°C for 20 min. The wells were washed three times
hen indicated. Transcription was initiated for 1 min in
he presence of ribonucleotides (NTPs) and
a-32P]UTP, followed by three washes. The reaction
as chased at 30°C for 8 min in a 25-ml volume
ontaining 4 mM sodium citrate, 625 mM concentration
ach of unlabeled ATP, CTP, GTP, and UTP, and 500
m
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345TAT ACTIVATION OF RNA POLYMERASE II COMPLEXESM IPTG when indicated in buffer D. Tat or K41A (Sun˜e´
nd Garcia-Blanco, 1995) (400 ng) was added to some
eactions at stages corresponding to the preinitiation
omplex formation or the elongation (see Fig. 1). In the
xperiment shown in Fig. 3, after the wash, the paused
ranscription complex was incubated for 20 min with
ither 400 ng of Tat or 12% (v/v) of NE, or both, in buffer
, before being chased with unlabeled NTPs and
PTG. The reaction was stopped, and RNA was iso-
ated and separated by electrophoresis on 6% polyac-
ylamide-urea gels. Bands on the gel were visualized
y autoradiography and quantified using a Phospho-
Imager (Molecular Dynamics). Quantification was
one so as to allow comparison of transcription
mong different reactions. Specific transactivation is
iven by the following formula:
Specific transactivation 5
Pf(1I/1T) 2 Pf(2I/2T)
Pf(1I/2T) 2 Pf(2I/2T)
here Pf(1I/1T) is the level of full-length transcript,
iven as a percentage of all transcripts, in the reaction
ontaining IPTG and Tat; Pf(1I/2T) is the level of full-
ength transcript, given as a percentage of all transcripts
n the reaction containing IPTG but no Tat; and Pf(2I/2T)
s the same percentage in a reaction without IPTG and
ithout Tat. The value of Pf(2I/2T) is almost identical to
hat of Pf(2I/1T) and was ,9% of that of Pf(1I/2T).
f(2I/2T) was used as the background for the assay.
he experiments shown in the manuscript were repeated
t least three times and gave consistent results.
epletion of endogenous ATP from nuclear extract
To deplete endogenous ATP from NE, a hexokinase
eaction was performed. [a-32P]ATP (3000 Ci/mmol) was
dded to NE at a final concentration of 4 nM, together
ith 12 mM glucose, and 2.5 mg/ml hexokinase (Sigma)
hen indicated. The hexokinase reactions were carried
ut at 30°C for 10 min. Samples of 1 ml were precipitated
ith 30 ml of 15% (w/v) trichloroacetic acid. The super-
atant fractions were neutralized with an equal volume of
N NaOH, and samples of 0.5 ml, together with 0.5 ml of
00 mM ATP, ADP, and AMP standards, were spotted
nto a polyethyleneimine-cellulose thin-layer chromatog-
aphy plate containing fluorescent indicator (Fisher) and
eveloped in a developing chamber containing 1 M LiCl
olution. Standards were visualized by UV light; [a-32P]ATP
nd other samples were visualized by autoradiography.
ACKNOWLEDGMENTS
We thank Kathleen S. Matthews for the generous gift of the lac
epressor. We thank Arno Greenleaf, Paul Bohjanen, Zvi Pasman, Aaron
oldstrohm, and Lars Lund for critical reading of the manuscript. We
re also grateful to Bryan Cullen, Arno Greenleaf, Paul Bohjanen, and
embers of the Garcia-Blanco laboratory for discussions and sugges-ions. We thank David H. Price for sharing results before publication.he authors wish to acknowledge the support of the Keck Foundation
o the Levine Science Research Center. This work was supported by a
rant from National Institutes of Health and funds from the VA Research
enter on AIDS and HIV Infection to (M.A.G.-B.).
REFERENCES
rya, S. K., Guo, C. S., Josephs, F. and Wong-Staal, F. (1985). Trans-
activator gene of human T-lymphotropic virus type III (HTLV-III).
Science 229, 69–73.
erger, J., Hauber, J., Hauber, R., Geiger, R., and Cullen, B. R. (1988).
Secreted placental alkaline phosphatase: A powerful new quantita-
tive indicator of gene expression in eukaryotic cells. Gene 66, 1–10.
erkhout, B., and Jeang, K.-T. (1989). Trans activation of human immu-
nodeficiency virus type 1 is sequence specific for both the single-
stranded bulge and loop of the trans-acting-responsive hairpin: A
quantitative analysis. J. Virol. 63, 5501–5504.
erkhout, B., and Jeang, K.-T. (1992). Functional roles for the TATA
promoter and enhancers in basal and Tat-induced expression of the
human immunodeficiency virus type 1 long terminal repeat. J. Virol.
66, 139–149.
erkhout, B. R., Silverman, H., and Jeang, K.-T. (1989). Tat trans-activates
the human immunodeficiency virus through a nascent RNA target.
Cell 59, 273–282.
lair, W. S., Fridell, R. A., and Cullen, B. R. (1996). Synergistic enhance-
ment of both initiation and elongation by acidic transcription activa-
tion domains. EMBO J. 15, 1658–1665.
lau, J., Xiao, H., McCracken, S., O’Hare, P., Greenblatt, L., and Bentley,
D. (1996). Three functional classes of transcriptional activation do-
main. Mol. Cell. Biol. 16, 2044–2055.
ohjanen, P. R., Liu, Y., and Garcia-Blanco, M. A. (1997). TAR RNA
decoys inhibit Tat-activated HIV-1 transcription after preinitiation
complex formation. Nucleic Acids Res. 25, 4481–4486.
arroll, R., Peterlin, B. M., and Derse, D. (1992). Inhibition of human
immunodeficiency virus type 1 Tat activity by coexpression of heter-
ologous trans activators. J. Virol. 66, 2000–2007.
ujec, T. P., Cho, H., Maldonado, E., Meyer, J., Reinberg, D., and
Peterlin, B. M. (1997a). The human immunodeficiency virus transac-
tivator Tat interacts with the RNA polymerase II holoenzyme. Mol.
Cell. Biol. 17, 1817–1823.
ujec, T. P., Okamoto, H., Fujinaga, K., Meyer, J., Chamberlin, H.,
Morgan, D. O., and Peterlin, B. M. (1997b). The HIV transactivator Tat
binds to the CDK-activating kinase and activates the phosphorylation
of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11,
2645–2657.
ullen, B. R. (1990). The HIV-1 Tat protein: An RNA sequence-specific
processivity factor? Cell 63, 655–657.
ullen, B. R. (1993). Does HIV-1 Tat induce a change in viral initiation
rights? Cell 73, 417–420.
euschele, U., Hipskind, R. A., and Bujard, H. (1990). RNA polymerase
II transcription blocked by Escherichia coli Lac repressor. Science
248, 480–483.
vir, A., Conaway, R. C., and Conaway, J. W. (1997). A role for TFIIH in
controlling the activity of early RNA polymerase II elongation com-
plexes. Proc. Natl. Acad. Sci. USA 94, 9006–9010.
vir, A., Garrett, K. P., Chalut, C., Egly, J.-M., Conaway, J. W., and
Conaway, R. C. (1996). A role for ATP and TFIIH in activation of the
RNA polymerase II preinitiation complex prior to transcription initia-
tion. J. Biol. Chem. 271, 7245–7248.
einberg, M. B., Baltimore, D., and Frankel, A. D. (1991). The role of Tat
in the human immunodeficiency virus life cycle indicates a primary
effect on transcriptional elongation. Proc. Natl. Acad. Sci. USA 88,
4045–4049.
eng, S., and Holland, E. C. (1988). HIV-1 Tat trans-activation requires
the loop sequence within TAR. Nature 334, 165–167.
ujinaga, K., Cujec, T. P., Peng, J., Garriga, J., Price, D. H., Grana, X., and
Peterlin, B. M. (1998). The ability of positive transcription elongation
GG
G
G
G
H
H
K
K
K
K
K
L
M
M
M
M
M
M
O
P
R
R
R
R
S
S
S
S
V
W
Y
Y
Y
Z
Z
Z
346 LIU, SU, AND GARCIA-BLANCOfactor b to transactivate human immunodeficiency virus transcription
depends on a functional kinase domain, cyclin T1, and Tat. J. Virol. 72,
7154–7159.
arcia-Martinez, L., Mavankal, G., Neveu, J., Lane, W., Ivanov, D., and
Gaynor, R. (1997). Purification of a Tat-associated kinase reveals a
TFIIH complex that modulated HIV-1 transcription. EMBO J. 16, 2836–
2850.
arcia-Martinez, L. F., Ivanov, D., and Gaynor, R. B. (1997). Association
of Tat with purified HIV-1 and HIV-2 transcription preinitiation com-
plex. J. Biol. Chem. 272, 6951–6958.
aynor, R. B. (1995). Regulation of HIV-1 gene expression by the
transactivator protein Tat. Curr. Top. Microbiol. Immunol. 193, 51–77.
oodrich, J., and Tjian, R. (1994). Transcription factors IIE and IIH and
ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell
77, 145–156.
reenblatt, J., Nodwell, J. R., and Mason, S. W. (1993). Transcriptional
antitermination. Nature 364, 401–406.
errmann, C. H., and Rice, A. P. (1993). Specific interaction of the
human immunodeficiency virus Tat proteins with a cellular protein
kinase. Virology 197, 601–608.
errmann, C. H., and Rice, A. P. (1995). Lentivirus Tat proteins specif-
ically associate with a cellular protein kinase, TAK, that hyperphos-
phorylates the carboxyl-terminal domain of the large subunit of RNA
polymerase II: candidate for a Tat cofactor. J. Virol. 69, 1612–1620.
ao, S.-Y., Calman, A. F., Luciw, P. A., and Peterlin, B. M. (1987). Anti-
termination of transcription within the long terminal repeat of HIV-1
by Tat gene product. Nature 330, 489–493.
ashanchi, F., Piras, G., Radonovich, M. F., Duvall, J. F., Fattaey, A.,
Chiang, C.-M., Roeder, R. G., and Brady, J. N. (1994). Direct interaction
of human TFIID with the HIV-1 transactivator Tat. Nature 367, 295–
299.
ato, H., Sumimoto, H., Pognonec, P., Chen, C.-H., Rosen, C. A., and
Roeder, R. G. (1992). HIV-1 Tat acts as a processivity factor in vitro in
conjunction with cellular elongation factors. Genes Dev. 6, 655–666.
een, N. J., Churcher, M. J., and Karn, J. (1997). Transfer of Tat and
release of TAR RNA during the activation of the human immunode-
ficiency virus type-1 transcription elongation complex. EMBO J. 17,
5260–5272.
een, N. J., Gait, M. J., and Karn, J. (1996). Human immunodeficiency
virus type-1 Tat is an integral component of the activated transcrip-
tion-elongation complex. Proc. Natl. Acad. Sci. USA 93, 2505–2510.
u, X., Welsh, T. M., and Peterlin, B. M. (1993). The human immunode-
ficiency virus type 1 long terminal repeat specifies two different
transcription complexes, only one of which is regulated by Tat.
J. Virol. 67, 1752–1760.
adore, S. J., and Cullen, B. R. (1993). Genetic analysis of the cofactor
requirement for human immunodeficiency virus type 1 Tat function.
J. Virol. 67, 3703–3711.
ancebo, H. S. Y., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y.,
Peng, J., Blau, C., Hazuda, D., Price, D., and Flores, O. (1997). P-TEFb
kinase is required for HIV Tat transcriptional activation in vivo and in
vitro. Genes Dev. 11, 2633–2644.
arciniak, R. A., Calnan, B. J., Frankel, A. D., and Sharp, P. A. (1990).
HIV-1 Tat protein trans-activates transcription in vitro. Cell 63, 791–
802.
arciniak, R. A., and Sharp, P. A. (1991). HIV-1 Tat protein promotes
formation of more-processive elongation complexes. EMBO J. 10,
4189–4196.
arshall, N., Peng, J., Xie, Z., and Price, D. H. (1996). Control of RNA
polymerase II elongation potential by a novel carboxyl-terminal do-
main kinase. J. Biol. Chem. 271, 27176–27183.
arshall, N., and Price, D. H. (1995). Purification of P-TEFb, a transcrip-
tion factor required for the transition into productive elongation.
J. Biol. Chem. 270, 12335–12338.lsen, H. S., and Rosen, C. A. (1992). Contribution of the TATA motif to
Tat-mediated transcriptional activation of human immunodeficiency
virus gene expression. J. Virol. 66, 5594–5597.
arada, C. A., and Roeder, R. G. (1996). Enhanced processivity of RNA
polymerase II triggered by Tat-induced phosphorylation of its car-
boxy-terminal domain. Nature 384, 375–378.
eines, D., and Mote, J. J. (1993). Elongation factor SII-dependent
transcription by RNA polymerase II through a sequence-specific
DNA-binding protein. Proc. Natl. Acad. Sci. USA 90, 1917–1921.
ice, A. P., and Carlotti, F. (1990). Structural analysis of wild-type and
mutant human immunodeficiency virus type 1 Tat proteins. J. Virol.
64, 1864–1868.
iggs, A. D., Newby, R. F., and Bourgeois, S. (1970). lac repressor–
operator interaction. II. Effect of galactosides and other ligands. J.
Miol. Biol. 51, 303–314.
osen, C. A., Sodroski, J. G., and Haseltine, W. A. (1985). The location of
cis-acting regulatory sequences in the human T cell lymphotropic
virus type III (HTLV-III/LAV) long terminal repeat. Cell 41, 813–
823.
elby, M. J., Bain, E. S., Luciw, P. A., and Peterlin, B. M. (1989). Structure,
sequence, and position of the stem-loop in TAR determine transcrip-
tional elongation by Tat through the HIV-1 long terminal repeat.
Genes Dev. 3, 547–558.
odroski, J., Patarca, R., Rosen, C., Wong-Staal, F., and Haseltine, W.
(1985). Location of the trans-activating region on the genome of
human T-cell lymphotropic virus type III. Science 229, 74–77.
un˜e´, C., and Garcia-Blanco, M. A. (1995). Transcriptional trans activa-
tion by HIV-1 Tat requires specific co-activators that are not basal
factors. J. Virol. 69, 3098–3107.
un˜e´, C., Hayashi, T., Liu, Y., Lane, W. S., Young, R. A., and Garcia-
Blanco, M. A. (1997). CA150, a nuclear protein associated with the
RNA polymerase II holoenzyme, is involved in Tat-activated human
immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 17, 6029–
6039.
eschambre, P., Roisin, A., and Jalinot, P. (1997). Biochemical and
functional interaction of the human immunodeficiency virus type 1
Tat transactivator with the general transcriptional factor TFIIB. J. Gen-
eral Virol. 78, 2235–2245.
ei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., and Jones, K. A. (1998).
A novel cdk9-associated c-type cyclin interacts directly with HIV-1
Tat and mediated its high-affinity, loop-specific binding to TAR RNA.
Cell 92, 451–462.
ang, X., Gold, M. O., Tang, D. N., Lewis, D. E., Aguilar-Cordova, E., Rice,
A. P., and Herrmann, C. H. (1997). Tak, an HIV Tat-associated kinase,
is a member of the cyclin-dependent family of protein kinases and is
induced by activation of peripheral blood lymphocytes and differen-
tiation of promonocytic cell lines. Proc. Natl. Acad. Sci. USA 94,
12331–12336.
ang, X., Herrmann, C. H., and Rice, A. P. (1996). The human immuno-
deficiency virus Tat proteins specifically associate with TAK in vivo
and require the carboxyl-terminal domain of RNA polymerase II for
function. J. Virol. 70, 4576–4584.
ankulov, K., Blau, J., Purton, T., Roberts, S., and Bentley, D. L. (1994).
Transcriptional elongation by RNA polymerase II is stimulated by
transactivators. Cell 77, 749–759.
hou, Q., and Sharp, P. A. (1995). Novel mechanism and factor for
regulation by HIV-1 Tat. EMBO J. 14, 321–328.
hou, Q., and Sharp, P. A. (1996). Tat-SF1: cofactor for stimulation of
transcriptional elongation by HIV-1 Tat. Science 274, 605–610.
hu, Y., Pe’ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T.,
Amendt, B., Mathews, M. B., and Price, D. H. (1997). Transcription
elongation factor P-TEFb is required for HIV-1 Tat transactivation in
vitro. Genes Dev. 11, 2622–2632.
